Charles Zhou
Stock Analyst at UBS
(0.68)
# 3,816
Out of 4,854 analysts
10
Total ratings
42.86%
Success rate
-12.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhou
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FUTU Futu Holdings | Maintains: Buy | $130 → $136 | $107.58 | +26.42% | 3 | Mar 17, 2025 | |
| ZYME Zymeworks | Reiterates: Buy | $16 | $12.13 | +31.90% | 1 | Mar 8, 2023 | |
| COGT Cogent Biosciences | Initiates: Buy | $15 | $5.99 | +150.42% | 1 | Jun 28, 2022 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.45 | - | 1 | May 5, 2022 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $56 | $0.95 | +5,794.74% | 1 | Aug 2, 2021 | |
| RPTX Repare Therapeutics | Initiates: Buy | $46 | $1.49 | +2,987.25% | 1 | Jun 28, 2021 | |
| QD Qudian | Downgrades: Neutral | n/a | $2.99 | - | 2 | Jan 22, 2020 |
Futu Holdings
Mar 17, 2025
Maintains: Buy
Price Target: $130 → $136
Current: $107.58
Upside: +26.42%
Zymeworks
Mar 8, 2023
Reiterates: Buy
Price Target: $16
Current: $12.13
Upside: +31.90%
Cogent Biosciences
Jun 28, 2022
Initiates: Buy
Price Target: $15
Current: $5.99
Upside: +150.42%
MacroGenics
May 5, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.45
Upside: -
PMV Pharmaceuticals
Aug 2, 2021
Initiates: Buy
Price Target: $56
Current: $0.95
Upside: +5,794.74%
Repare Therapeutics
Jun 28, 2021
Initiates: Buy
Price Target: $46
Current: $1.49
Upside: +2,987.25%
Qudian
Jan 22, 2020
Downgrades: Neutral
Price Target: n/a
Current: $2.99
Upside: -